Merck & Co Inc (MRK) reported strong third-quarter earnings, exceeding analysts’ expectations. While Keytruda, Merck’s blockbuster cancer immunotherapy, continued its impressive growth, Gardasil sales declined due to weaker demand in China. Despite the Gardasil challenges, analysts remain optimistic about Merck’s future, citing the strong performance of other key franchises and the potential of new products.
Merck (MRK) closed the trading day down 1.43%, lagging behind the broader market gains. While the company is projected to report strong earnings in the coming months, investors are cautious, leading to a recent stock decline. The article examines key financial data, analyst estimates, and valuation metrics to understand the current market sentiment surrounding Merck.
Merck & Company (MRK) stock is experiencing a surge today after the company announced it has finalized negotiations with the pan-Canadian Pharmaceutical Alliance for its drug WELIREG. This agreement paves the way for WELIREG to be publicly reimbursed in Canada, a significant step forward for the drug’s accessibility in the country.
